Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
    • Contact Us
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
Home > Safety Info > Safety Communication > Safety Alerts > Reports of serious adverse reactions with Ceftriaxone injection due to
unintentional mixing during reconstitution.

Reports of serious adverse reactions with Ceftriaxone injection due to
unintentional mixing during reconstitution.

Abdul Qadir Safety Alerts March 24, 2025March 24, 2025
Advisory-on-reports-of-serious-adverse-reactions-with-Ceftriaxone-injection-due-to-unintentional-mixing-during-reconstituDownload

Share this:

  • Twitter
  • Facebook
  • ← Safety Alert of Risk of Medication Errors resulting due to inadvertent intrathecal Tranexamic Acid Injection
  • Disposal of Short Shelf Life Cases →
  • Product Recalls
    • Recall Alerts
    • Therapeutic Products Recalls
    • Recalls and Rapid Alerts
  • Safety Communication
    • Safety Alerts
    • Pharmacovigilance Newsletter
    • Health Professional Alerts
  • Safety Reporting
    • How DRAP Monitor Safety
    • How to Report Adverse Events?
    • Pharmacovigilance System
  • Report a Problem
    • Reporting Adverse Events
    • Product Quality Defects
    • Hospital Medicine Shortage Reporting
    • COVID-19 Vaccine

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem